Myocarditis Temporally Associated With COVID-19 Vaccination
- Other version(s) of this article
-
You are viewing the most recent version of this article. Previous versions:
-
The global coronavirus disease 2019 (COVID-19) pandemic brought significant mortality with more than 3 million deaths worldwide since January 2020.1 Concerted efforts focused on the time-sensitive development of vaccines yielded 3 COVID-19 vaccines receiving provisional US Food and Drug Administration approval: Pfizer-BioNTech COVID-19 (BNT162b2; Pfizer, Inc; Philadelphia, PA), Moderna (mRNA-1273; ModernaTX, Inc; Cambridge, MA), and Janssen (Ad.26.COV2.S; Johnson and Johnson; New Brunswick, NJ).1 All vaccines demonstrated excellent safety and clinical efficacy profiles in clinical trials. As of June 5, 2021, more than 170 million individuals in the United States and 894 million individuals worldwide had received at least 1 dose of a COVID-19 vaccine. Notwithstanding isolated rare serious adverse events, they have been well tolerated and associated with decreasing burden of disease in areas with high vaccination rates.2
Myopericarditis has been reported as a rare vaccination complication.3 We present a case series of 7 patients hospitalized for acute myocarditis-like illness after COVID-19 vaccination, from 2 US medical centers in Falls Church, VA, and Dallas, TX. All were men <40 years of age and of White or Hispanic race/ethnicity (Table). Only 1 patient reported previous history of COVID-19 infection. Six patients received an mRNA vaccine (Moderna or Pfizer/BioNTech), and 1 received the adenovirus vaccine (Johnson and Johnson). All patients presented 3 to 7 days after vaccination with acute onset chest pain and biochemical evidence of myocardial injury, by cTnI ([cardiac troponin I]; Abbott Diagnostics, Lake Forest, IL) (mean peak, 15.77 ng/mL; median peak, 12.01 ng/mL) or elevated high-sensitivity cTnI (Abbott Diagnostics) (peak, 7000 ng/L). All were hemodynamically stable and none had a pericardial friction rub or rash. ECG patterns varied from normal to ST segment elevation. Three patients underwent invasive coronary angiography, and none had evidence of obstructive coronary artery disease. Echocardiograms showed left ventricular ejection fraction ranging from 35% to 62%, with 5 of 7 having some degree of hypokinesis. Patients underwent cardiac magnetic resonance imaging between 3 and 37 days after vaccination, including multiplanar SSFP sequences, short axis T1 and T2 stacks, T1 mapping when available and multiplanar myocardial late gadolinium enhancement. Multifocal subepicardial late gadolinium enhancement was present in 7 of 7 patients and additional midmyocardial late gadolinium enhancement was 4 of 7 patients. There was corresponding myocardial edema in 3 of 7 patients. Two patients who underwent cardiac magnetic resonance imaging >7 days from presentation had no edema, with an additional patient’s T2 images limited by artifact. One patient underwent endomyocardial biopsy without pathological evidence of myocarditis. No patients reported palpitations, and there was no evidence of sustained arrhythmias. No patients had evidence of an active viral illness or autoimmune disease, and 6 of 7 had polymerase chain reaction testing for acute COVID-19 infection during hospitalization (all 6 were negative). Assessment of COVID-19 serology was obtained for 6 of 7 patients, with 4 of 6 showing presence of spike protein IgG antibodies.
Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | Case 6 | Case 7 | |
---|---|---|---|---|---|---|---|
Age, y | 28 | 39 | 39 | 24 | 19 | 20 | 23 |
Sex | M | M | M | M | M | M | M |
Race/ethnicity | White | White | White | White | Hispanic | White | White |
Vaccine type | |||||||
mRNA | Y (Pf, 2nd) | Y (Mod, 2nd) | Y (Pf, 1st) | Y (Pf, 2nd) | Y (Pf, 2nd) | Y (Pf, 2nd) | |
Adenovirus | Y (J&J) | ||||||
Days from administration to presentation | 5 | 3 | 4 | 7 | 2 | 3 | 3 |
History of previous COVID-19 infection | Denied/remote negative PCR | Denied/negative PCR | Denied/negative PCR | Denied/negative PCR | Denied/negative PCR | Yes/negative PCR | Denied/negative PCR |
Presenting symptoms | Chest pain at rest, nonpleuritic, nonexertional; no fevers, coughing, or shortness of breath |
Sudden onset 7 out of 10 chest pain 2 days after vaccine, associated with shortness of breath; worse when lying flat and with inspiration | Fever, chills, shortness of breath, and chest heaviness/pain symptoms | Intermittent, positional chest pain with left arm numbness and tingling | Midsternal sharp chest pain, waxing/and positional; relieved with leaning forward | Midsternal chest pain with deep inspiration. | Subjective fevers, diffuse myalgia, and headache starting day of vaccination; sudden onset of sharp chest pain the night before admission that persisted at 3 out of 10 intensity, worsened when lying flat |
Vital signs at presentation | |||||||
Temperature, °C | 37 | 36.6 | 36.9 | 36.9 | 36.5 | 37.9 | 37.1 |
Heart rate, bpm | 70 | 93 | 79 | 69 | 77 | 112 | 96 |
Blood pressure, mm Hg | 145/82 | 116/76 | 103/70 | 114/56 | 108/71 | 121/78 | 131/80 |
Respirations, per min | 18 | 18 | 16 | 16 | 18 | 18 | 16 |
Chest x-ray findings | No acute pulmonary disease | No acute process | No detectable active cardiopulmonary disease | No acute abnormality | No acute disease | No evidence of acute cardiopulmonary disease | No acute abnormality |
ECG findings | |||||||
ST changes | 1-mm ST elevation in II, V5–V6 | PR depression in II, aVF, V4–V6 T wave inversion V1 |
No acute ST segment changes | No acute ST segment changes | Nonspecific ST-T changes | 1-mm ST elevation V2–V5 | Diffuse ST elevations |
Rhythm | Normal sinus rhythm | Normal sinus rhythm | Normal sinus rhythm | Normal sinus rhythm | Normal sinus rhythm | Sinus tachycardia | Sinus tachycardia |
Echocardiogram | 6 days postvaccine | 3 days postvaccine | 4 days postvaccine | 7 days postvaccine | 2 days postvaccine | 5 days postvaccine | 4 days postvaccine |
Left ventricular ejection fraction | 51% | 35% to 40% | 61% | 53% | 55% | 50% to 55% | 58% |
Left ventricular end-diastolic internal dimension | 4.8 cm | 4.9 cm | 4.4 cm | 5.2 cm | 4.7 cm | 4.34 cm | 5.0 cm |
Intraventricular septal diastolic thickness (2D) | 1.0 cm | 1.1 cm | 1.0 cm | 1.0 cm | 0.6 cm | 1.1 cm | 1.0 cm |
Regional wall motion abnormalities | Mild global hypokinesis | Mild global left ventricular hypokinesis; mildly decreased right ventricular function | None | None | None | Mild hypokinesis in the mid- to distal anteroseptum and apex | None |
Diastolic function | Normal | Normal | Normal | Normal | Normal | Normal | Normal |
Cardiac magnetic resonance imaging | 37 days postvaccine | 11 days postvaccine | 5 days postvaccine | 7 days postvaccine | 3 days postvaccine | 6 days postvaccine | 3 days postvaccine |
Left ventricular ejection fraction | 50% (no regional wall motion abnormalities) | 56% (no regional wall motion abnormalities) | 52% (no regional wall motion abnormalities) | 48% (no regional wall motion abnormalities) | 50% (no regional wall motion abnormalities) | 52% (subtle apical septal and apical lateral hypokinesis) | 50% (no regional wall motion abnormalities) |
LGE | Patchy mild subepicardial LGE throughout the mid- to apical left ventricular walls; no pericardial thickening or enhancement |
Subepicardial LGE along the anterior and lateral walls; no pericardial thickening or effusion | Multifocal subepicardial and midmyocardial LGE; prominence of the pericardium overlying the anterior wall with enhancement | Midmyocardial LGE in the septal and inferior walls; subepicardial LGE in the anterior, lateral, and inferior walls; no pericardial effusion | Multifocal patchy subepicardial and midmyocardial LGE within the lateral and inferolateral walls; no pericardial thickening or enhancement |
Subepicardial LGE within the lateral, inferolateral, and anterolateral walls with global left ventricular apex; no pericardial thickening or effusion | Basal anteroseptal mid wall delayed enhancement; trace pericardial enhancement |
T1 mapping | 1046 ms | 1000 ms | 1125 ms | ||||
T2 | No definitive edema | No definitive edema | Suboptimal T2 WI secondary to banding artifact and respiratory motion | Myocardial edema in the lateral and inferior walls | Myocardial edema in lateral wall at the level of the base | Subtle inferior wall myocardial edema | No definitive edema |
White blood cell count | 8.08 | 9.01 | 8.28 | 11.14 | 8.33 | 10.56 | 9.46 |
Cardiac troponin I ng/mL (<0.04 ng/mL) | |||||||
Presentation | 3.55 | 4.24 | 3.41 | 0.37 | 4.49 | 0.48 | |
Peak | 17.08 | 11.01 | 13.00 | 0.37 | 44.80 | 8.36 | |
Postdischarge | <0.01 | <0.01 | 0.037 | ND | 0.19 | ND | |
cTnI, ng/L (<17 ng/L) | |||||||
Presentation | 2601 | ||||||
Peak | 7000 | ||||||
Postdischarge | 6 | ||||||
B-type natriuretic peptide, pg/mL | ND | 22 | 97 | <10 | 57.2 | 29 | 68 |
Erythrocyte sedimentation rate peak, mm/h | 8 | 8 | 23 | 4 | ND | 10 | 32 |
C-reactive protein peak, mg/dL | 1.3 | 5.1 | 11.70 | 0.1 | 3.1 | 8.2 | 7.3 |
Antinuclear antibody screen | Negative | Negative | Negative | ND | Negative | ND | ND |
SARS-CoV-2 antibody | |||||||
Spike IgG | Negative*‡ | Positive* | Positive‡ | Negative§ | Positive* | ND | Positive† |
Nucleocapsid IgG | Negative† | Negative† | ND | ND | Negative† | ND | Negative† |
Respiratory viral panel∥ | ND | ND | Negative except mycoplasma IgG; Coxsackie B1, B2, B3 (IgG 1:8) and B4, B5, B6 (IgG 1:16) | Negative | Negative | Negative | Negative except Coxsackie B4 (IgG 1:320) |
Coronary angiography findings | No evidence of coronary artery disease | No evidence of coronary artery disease | No obstructive coronary artery disease; proximal circumflex; mild 30% stenosis | ND | ND | ND | ND |
Clinical course | |||||||
Hospitalization duration | 2 days | 4 days | 3 days | 2 days | 3 days | 4 days | 2 days |
Treatment(s) | β-blocker, angiotensin-converting enzyme inhibitor, aspirin, and clopidogrel (2 doses, stopped on discharge) | β-blocker, angiotensin receptor blocker, statin | 3 days IV steroids | Colchicine, ibuprofen, famotidine | Colchicine, ibuprofen, famotidine | Ibuprofen, famotidine | β-blocker, colchicine |
Treatment varied and included β-blocker and anti-inflammatory medication. Hospital length of stay was 3±1 days, and all patients’ symptoms resolved by hospital discharge. All cases were reported to the Vaccine Adverse Event Reporting System and the Centers for Disease Control. Institutional review board approval was obtained for this report. The data that support the findings of this study are available from the corresponding author on reasonable request.
In 1990, the United States established the Vaccine Adverse Event Reporting System and from 1990 to 2018, myopericarditis comprised 0.1% of all adverse events reported.3 To date, while anecdotes of potential myocarditis from COVID-19 vaccines have been reported in the lay media4 and the US Centers for Disease Control and Prevention has acknowledged investigation of potential cases, to our knowledge there are no reported case series of myocarditis-like illness associated with COVID-19 vaccination in adults. Our series of 7 male COVID-19 vaccination recipients who presented with myocarditis-like illness supports a potential causal association with vaccination given the temporal relationship, clinical presentation, and cardiac magnetic resonance imaging findings. Although endomyocardial biopsy was negative in the single case in which it was performed, this may represent sampling bias, given the patchy nature of myocardial inflammation in myocarditis.5 Of the 2 patients without measurable spike protein IgG, both presented shortly after their first vaccine dose. This antibody response is not unexpected but may indicate an alternate vaccine-related immune mechanism or absence of causality with the vaccine.
Additional study is needed to confirm whether the rate of myocarditis-like illness is higher after vaccination than the background rate of myocarditis among similarly aged individuals in the population. Globally, myocarditis is diagnosed in approximately 10 to 20 individuals per 100 000 person-years.5 Moreover, careful immunophenotyping studies are needed to investigate potential mechanisms of vaccine-associated myocardial injury. Such studies could help determine populations at higher risk of this potential outcome and possible treatment strategies and should inform clinicians of the possibility of a myocarditis-like illness in patients with appropriate symptoms in the first few days after COVID-19 vaccination. Treatment considerations for myocarditis include anti-inflammatory medications and the addition of guideline-directed medical therapy if left ventricular ejection fraction is reduced,5 although no data specific to vaccine-associated myocarditis are available.
The clinical course of vaccine-associated myocarditis-like illness appears favorable, with resolution of symptoms in all patients. Given the potential morbidity of COVID-19 infection even in younger adults, the risk–benefit decision for vaccination remains highly favorable. Vaccine adverse event reporting remains of high importance and further studies are needed to elucidate the pathophysiological mechanism to potentially identify or prevent future occurrences.
Nonstandard Abbreviations and Acronyms
COVID-19 | coronavirus disease 2019 |
cTnI | cardiac troponin I |
Acknowledgments
The authors acknowledge the Dudley Family for their continued contributions and support of the Inova Dudley Family Center for Cardiovascular Innovation. The authors also acknowledge Kee Hyo Kang, Dr Lucy Nam, and Holly O’Donnell for their laboratory contributions and support of this project.
Sources of Funding
Dr Damluji receives research funding from the Pepper Scholars Program of the Johns Hopkins University Claude D. Pepper Older Americans Independence Center funded by the National Institute on Aging (P30-AG021334) and a Mentored Patient-Oriented Research Career Development Award from the National Heart, Lung, and Blood Institute (K23-HL153771-01). Dr deFilippi receives funding from the National Center for Advancing Translational Science of the National Institutes of Health (award UL1TR003015).
Disclosures Dr Tehrani is a consultant for Medtronic, and is on the advisory board for Abbott Medical and Retriever Medical. Dr Atkins is on the advisory board for Arterys. Dr de Lemos has received grant support from Abbott Diagnostics and Roche Diagnostics and consulting income from Siemen’s Health Care Diagnostics, Ortho Clinical Diagnostics, and Quidel, Inc. Dr Desai serves on the Advisory Board at Abbott Medical. Dr. Muthukumar has received grant support from Abbott and Roche Diagnostics. Dr deFilippi receives research funding to Inova from Abbott Diagnostics, Roche Diagnostics, Siemens Healthineers, and Ortho Diagnostics; and consults for FujiRebio, Roche Diagnostics, Siemens Healthineers, and Ortho Diagnostics. The other authors report no conflicts.
Footnotes
References
- 1.
Damluji AA, Christenson RH, deFilippi C . Clinical application of serologic testing for coronavirus disease 2019 in contemporary cardiovascular practice.J Am Heart Assoc. 2021; 10:e019506. doi: 10.1161/JAHA.120.019506LinkGoogle Scholar - 2.
Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, Sudre CH, Nguyen LH, Drew DA, Merino J, . Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.Lancet Infect Dis. 2021; 7:939–949.CrossrefGoogle Scholar - 3.
Su JR, McNeil MM, Welsh KJ, Marquez PL, Ng C, Yan M, Cano MV . Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990-2018.Vaccine. 2021; 39:839–845. doi: 10.1016/j.vaccine.2020.12.046CrossrefMedlineGoogle Scholar - 4.
Mandavilli A . C.D.C. is investigating a heart problem in a few young vaccine recipients.The New York Times. May 22, 2021. https://www.nytimes.com/2021/05/22/health/cdc-heart-teens-vaccination.html?smid=em-share. Accessed May 25, 2021.Google Scholar - 5.
Tschöpe C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB, Hare JM, Heidecker B, Heymans S, Hübner N, . Myocarditis and inflammatory cardiomyopathy: current evidence and future directions.Nat Rev Cardiol. 2021; 18:169–193. doi: 10.1038/s41569-020-00435-xCrossrefMedlineGoogle Scholar
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.